Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRE | P78334 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12587298 | 0.83 | CA1 (0.54) | ALDH1A1CA1TSHRTDP1BBOX1 | |
| SCHEMBL18124258 | 0.79 | TDP1 (0.36) | CA1TSHRTDP1GABRPGABRD | |
| SCHEMBL13469005 | 0.77 | THRB (0.39) | ALDH1A1 | |
| SCHEMBL21078232 | 0.76 | TDP1 (0.32) | CA1TSHRTDP1 | |
| SCHEMBL15759387 | 0.76 | TDP1 (0.44) | ALDH1A1CA1TSHRTDP1 | |
| SCHEMBL17211864 | 0.76 | TSHR (0.32) | CA1TSHR | |
| Methacrylic Acid SCHEMBL7773092 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHRCYP3A4GAAGABRP | |
| SCHEMBL15874792 | 0.76 | TSHR (0.32) | CA1TSHR | |
| Methacrylic Acid SCHEMBL2540763 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1GABRPGABRD | |
| Methacrylic Acid SCHEMBL9779507 | 0.75 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20170340623-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9684095-B2 | Hydrophilized carbosiloxane vinylic monomers | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| US-9408840-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | ARDELYX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160220503-A1 | METHOD FOR MAKING CUSTOMISED NANOPARTICLES, NANOPARTICLES AND USES THEREOF | ETH ZURICH (CH) | 2016-08-04 | — | — | US | disclosed |
| US-20150309210-A1 | HYDROPHILIZED CARBOSILOXANE VINYLIC MONOMERS | ALCON INC. (CH) | 2015-10-29 | — | — | US | disclosed |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | ARDELYX, INC. (US) | 2015-07-09 | — | — | US | disclosed |
| US-9006281-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8969377-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140186445-A1 | METHOD FOR MAKING CUSTOMISED NANOPARTICLES, NANOPARTICLES AND USES THEREOF | ETH ZURICH (CH) | 2014-07-03 | — | — | US | disclosed |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8541448-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20130236968-A1 | MULTIFUNCTIONAL COPOLYMERS FOR NUCLEIC ACID DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140186445-A1 | METHOD FOR MAKING CUSTOMISED NANOPARTICLES, NANOPARTICLES AND USES THEREOF | MSN, CD14, SAMM50 | ALDH1A1 2301/4885CA1 3334/4885TSHR 3424/4885 |
| US-20150190389-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER | SLC9A1, SLC9A2, SLC10A2 | ALDH1A1 3416/4885CA1 1146/4885TSHR 306/4885 |
| US-20120263670-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | ALDH1A1 1732/4885CA1 3458/4885TSHR 688/4885 |
| US-20170340623-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885CA1 2173/4885TSHR 680/4885 |
| US-20160220503-A1 | METHOD FOR MAKING CUSTOMISED NANOPARTICLES, NANOPARTICLES AND USES THEREOF | MSN, CD14, SAMM50 | ALDH1A1 2301/4885CA1 3334/4885TSHR 3424/4885 |
| US-20140107074-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A2, SLC9A1, SLC9A2 | ALDH1A1 3272/4885CA1 1426/4885TSHR 239/4885 |
| US-20150309210-A1 | HYDROPHILIZED CARBOSILOXANE VINYLIC MONOMERS | VCL, MACF1, HCAR1 | ALDH1A1 1488/4885CA1 328/4885TSHR 3251/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | ALDH1A1 2512/4885CA1 2173/4885TSHR 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.